Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL364771 | 0.90 | GAA (0.49) | GAAHPGDALDH1A1SMN1; SMN2ABL1 | |
| SCHEMBL12683792 | 0.90 | HPGD (0.51) | GAAHPGDALDH1A1SMN1; SMN2ABL1 | |
| SCHEMBL363951 | 0.87 | GAA (0.46) | GAAHPGDALDH1A1SMN1; SMN2ABL1 | |
| SCHEMBL8349593 | 0.87 | GAA (0.46) | GAAHPGDALDH1A1SMN1; SMN2ABL1 | |
| SCHEMBL9617792 | 0.87 | CA12 (0.44) | GAAHPGDALDH1A1SMN1; SMN2ABL1 | |
| SCHEMBL4508725 | 0.87 | HPGD (0.46) | GAAHPGDALDH1A1SMN1; SMN2ABL1 | |
| SCHEMBL23291790 | 0.85 | SOS1 (0.47) | GAAHPGDALDH1A1SMN1; SMN2ABL1 | |
| SCHEMBL22836884 | 0.85 | CFTR (0.45) | GAAHPGDALDH1A1SMN1; SMN2ABL1 | |
| SCHEMBL22836950 | 0.85 | GAA (0.43) | GAAHPGDALDH1A1SMN1; SMN2ABL1 | |
| SCHEMBL3337570 | 0.85 | SOS1 (0.47) | GAAHPGDALDH1A1SMN1; SMN2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022100-A1 | NAV1.8 INHIBITOR | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2026-01-22 | — | — | US | disclosed |
| EP-4545517-A1 | NAV1.8 INHIBITOR | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-04-30 | — | — | EP | disclosed |
| US-20240150277-A1 | Covalent PPARG inverse-agonists | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-09 | — | — | US | disclosed |
| US-20240083908-A1 | TETRAHYDROTHIENOPYRIMIDINESULFONAMIDE COMPOUNDS | ALIVEXIS, INC. (JP) | 2024-03-14 | — | — | US | disclosed |
| WO-2023246867-A1 | NAV1.8 INHIBITOR | 武汉人福创新药物研发中心有限公司 | 2023-12-28 | — | — | WO | disclosed |
| CN-117263856-A | Nav1.8 inhibitors | 武汉人福创新药物研发中心有限公司 | 2023-12-22 | — | — | CN | disclosed |
| EP-4269415-A1 | TETRAHYDRO THIENOPYRIDINE SULFONAMIDE COMPOUND | Modulus Discovery, Inc. (JP) | 2023-11-01 | — | — | EP | disclosed |
| EP-4269415-A1 | TETRAHYDRO THIENOPYRIDINE SULFONAMIDE COMPOUND | Modulus Discovery, Inc. (JP) | 2023-11-01 | — | — | EP | disclosed |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-14 | — | — | US | disclosed |
| CN-116583286-A | Tetrahydrothienopyrimidine sulfonamide compounds | 某久拉斯株式会社 | 2023-08-11 | — | — | CN | disclosed |
| WO-2022138812-A1 | TETRAHYDRO THIENOPYRIDINE SULFONAMIDE COMPOUND | モジュラス株式会社 | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083908-A1 | TETRAHYDROTHIENOPYRIMIDINESULFONAMIDE COMPOUNDS | TYMS, TYMP, TPMT | GAA 3336/4885HPGD 512/4885ALDH1A1 2342/4885 |
| US-20240150277-A1 | Covalent PPARG inverse-agonists | PPARG, PPARD, PPARA | GAA 2842/4885HPGD 343/4885ALDH1A1 1224/4885 |
| US-20260022100-A1 | NAV1.8 INHIBITOR | SCN8A, SCN1B, SCN1A | GAA 4429/4885HPGD 3251/4885ALDH1A1 853/4885 |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN10A | GAA 2969/4885HPGD 1512/4885ALDH1A1 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.